CA3015358C - Proteines de fusion d'enzymes lysosomales therapeutiques ciblees, formulations associees et leurs utilisations - Google Patents

Proteines de fusion d'enzymes lysosomales therapeutiques ciblees, formulations associees et leurs utilisations

Info

Publication number
CA3015358C
CA3015358C CA3015358A CA3015358A CA3015358C CA 3015358 C CA3015358 C CA 3015358C CA 3015358 A CA3015358 A CA 3015358A CA 3015358 A CA3015358 A CA 3015358A CA 3015358 C CA3015358 C CA 3015358C
Authority
CA
Canada
Prior art keywords
formulation
concentration
administration
decline
sodium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3015358A
Other languages
English (en)
Other versions
CA3015358A1 (fr
Inventor
Saeed Moshashaee
Jason K. Pinkstaff
Adam Shaywitz
Natalie Ciaccio
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Priority claimed from PCT/US2017/019343 external-priority patent/WO2017147414A1/fr
Publication of CA3015358A1 publication Critical patent/CA3015358A1/fr
Application granted granted Critical
Publication of CA3015358C publication Critical patent/CA3015358C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne en général des protéines de fusion d'enzymes lysosomales thérapeutiques utiles pour traiter des maladies lysosomales, des formulations liquides comprenant de telles protéines de fusion et des procédés associés utiles pour traiter des maladies lysosomales chez des mammifères.
CA3015358A 2016-02-24 2017-02-24 Proteines de fusion d'enzymes lysosomales therapeutiques ciblees, formulations associees et leurs utilisations Active CA3015358C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662299188P 2016-02-24 2016-02-24
US62/299,188 2016-02-24
US201662428221P 2016-11-30 2016-11-30
US62/428,221 2016-11-30
PCT/US2017/019343 WO2017147414A1 (fr) 2016-02-24 2017-02-24 Protéines de fusion d'enzymes lysosomales thérapeutiques ciblées, formulations associées et leurs utilisations

Publications (2)

Publication Number Publication Date
CA3015358A1 CA3015358A1 (fr) 2017-08-31
CA3015358C true CA3015358C (fr) 2025-09-23

Family

ID=

Similar Documents

Publication Publication Date Title
US20240263160A1 (en) Targeted Therapeutic Lysosomal Enzyme Fusion Proteins, Associated Formulations and Uses Thereof
US11065307B2 (en) Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety
AU2011270672B2 (en) Treatment of Sanfilippo Syndrome type B
US10301369B2 (en) Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteins
RU2671503C2 (ru) Способы и композиции для доставки в цнс арилсульфатазы а
KR20190103320A (ko) 안정화된 알파-갈락토시다제를 이용하는 파브리의 치료를 위한 치료적 요법
CA3015358C (fr) Proteines de fusion d'enzymes lysosomales therapeutiques ciblees, formulations associees et leurs utilisations
HK40001779B (en) Improved naglu fusion protein formulation
HK40001779A (en) Improved naglu fusion protein formulation
US20220133863A1 (en) Treatment of sanfilippo syndrome type b
RU2783380C2 (ru) Способы и композиции для доставки в цнс арилсульфатазы а
WO2017015375A1 (fr) Traitement d'une déficience cognitive de la mucopolysaccharidose de type iiia par administration intrathécale d'héparane n-sulfatase